Form 4: Ironwood Pharmaceuticals CEO Thomas McCourt Reports Stock Sale and Acquisition

CEO Thomas McCourt reports the sale of shares to cover tax obligations and acquisition of restricted stock units.

Summary

• Thomas McCourt, CEO of Ironwood Pharmaceuticals, reported a transaction on May 16, 2025, involving the sale of 13,353 shares of Class A Common Stock at $0.58 per share to cover tax withholding obligations related to vesting restricted stock units.
• Following this transaction, McCourt directly owns 1,147,281 shares of Class A Common Stock.
• On May 20, 2025, McCourt acquired 540,000 shares of Class A Common Stock through a restricted stock unit award at $0.
• Following this transaction, McCourt directly owns 1,687,281 shares of Class A Common Stock.
• The restricted stock units vest in three equal installments on each anniversary of the grant.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations.

Positives

• The acquisition of 540,000 shares through restricted stock units demonstrates continued alignment of the CEO's interests with the company's performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock units implies a multi-year commitment from the CEO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading. They provide investors with insights into the transactions of company executives and directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the acquisition of restricted stock units signals continued commitment from the CEO.

Key Dates

Keywords

Ironwood Pharmaceuticals, Thomas McCourt, Form 4, Stock Sale, Restricted Stock Units, Beneficial Ownership, IRWD